Goa inks MoU with Starlink to explore satellite internet for smart governance, disaster response
Wife of this billionaire buys MF Hussain's painting for Rs 118 crore, details here
T20I World Cup 2026: BCB makes another request to ICC, asks for more time to talk to Bangladesh govt
Trump calls PM Modi 'fantastic leader,' says will have 'great deal' with India
DNA TV Show: India's hypersonic vision on Republic Day 2026 parade
Deepinder Goyal resigns as Zomato CEO: Know his net worth, Eternal Q3 profit and more
HEALTH
Dr VK Paul, Member (Health), NITI Aayog said while one vaccine is in the stage of phase-3 trials, the other two are also progressing well and are in the phase 1-2 of clinical trials. He said the government has asked manufacturers to indicate what possible prices could be.
The Central government has asked vaccine manufacturers indicate potential prices of COVID vaccines as they enter the clinical trial stage, an official said on Tuesday.
Dr VK Paul, Member (Health), NITI Aayog said while one vaccine is in the stage of phase-3 trials, the other two are also progressing well and are in the phase 1-2 of clinical trials.
"We have reviewed all these vaccine candidates. These are progressing well and their developments are taking place in a reassuring manner," he said.
“The outline of vaccine administration and supply chain is ready. As and when required, detailed and micro-level planning for vaccine administration based on a scientific approach according to the characteristics of the vaccine will be adopted”, he added.
Stating that discussions are going on with the vaccine manufacturers, Dr Paul said the government has asked manufacturers to indicate what possible prices could be.
“We requested the vaccine manufacturers to indicate what possible prices could be. Pricing is very complex as some of these vaccines are at an early stage. We have some insights into what the price range could be, but this is an information that will be refined as we move along," Dr Paul said.
He further stated that the government held discussions with vaccine manufacturers to know about the facilitations they are expecting.
He said that individual vaccine manufacturers have been requested to provide more clear-cut data on their individual production capacities and how their capacities would pan out with time, encouraging them very actively to ramp up capacity with facilitations. "This is a dialogue in motion".
India has huge potential and capacity in vaccine manufacturing, he said.
Earlier on Monday, National Expert Group on Vaccine Administration met leading domestic vaccine manufactures- Serum Institute of India, Pune; Bharat Biotech, Hyderabad; Zydus Cadila, Ahmedabad; Gennova Biopharmaceuticals, Pune; and Biological E, Hyderabad.
The meeting provided the National Expert Group with inputs about the present stage of various candidate vaccines being developed by the indigenous manufacturers as well as their expectations from the Union Government.